Key points are not available for this paper at this time.
As countries revise guidelines to provide ART to all people living with HIV and continue to scale up access to viral load, strategic choices will need to be made regarding future investments in CD4 cell count and the appropriate use for clinical disease management.
Ford et al. (Fri,) studied this question.